# Sage Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sage-science

- Industry: Biotechnology
- Headquarters: Beverly Hills, US
- Website: www.sagescience.com
- Total disclosed funding: $0.1M
- Latest round: Series A (Apr 24, 2007)
- Investors on record: 2

## About

Sage Science, Inc. specializes in advanced genomic technologies, providing innovative solutions for DNA and RNA analysis, catering to the needs of academic and research institutions globally.Founded in 2005 and headquartered in Beverly Hills, US, Sage Science, Inc. focuses on the development of genomic technologies. The company has not undergone any significant pivots in its strategy or operations. Todd Barbera leads as CEO, and the firm has attracted interest from investors through its Series A funding round in April 2007, which raised USD 80 thousand from Brooke Private Equity Associates and Village Ventures. The total amount raised by the company stands at USD 80 thousand, with a current valuation of USD 2.723 mn.Sage Science specializes in advanced genomic technologies and solutions that facilitate high-quality DNA and RNA analysis. Their core product offerings include the HMW (High Molecular Weight) DNA extraction system, which enables the isolation of DNA fragments ranging from 100 bp to 500 kDa, and the Cas9-based HLS-CATCH technology that captures genomic regions up to 500 Kb for targeted sequencing. These innovations cater to various applications, such as next-generation sequencing (NGS) sample preparation, RNA-seq workflows, and massively parallel genotyping through ddRAD-seq methods. The company serves a diverse client base, including academic institutions, research organizations, and agricultural entities, particularly in North America, Europe, and Asia, focusing on enhancing genomic research for improved crop resilience and broader applications in life sciences.While specific revenue figures are not disclosed, Sage Science engages in B2B transactions with its clients, which include universities and research institutes. The company’s revenue model involves direct sales of its flagship products, such as the Megaruptor3 and Pippin systems, alongside potential subscription services for ongoing support and software updates related to their genomic technologies. Transactions typically revolve around the sale of equipment and reagents necessary for genomic analysis, supplemented by workshops and webinars aimed at educating customers on best practices and applications of their technologies. The combination of these offerings suggests a structured pricing model that aligns with the needs of the research and agricultural sectors, facilitating ongoing partnerships and collaborations.Sage Science's future growth strategy includes plans to expand its product line, focusing on new genomic technologies that enhance analysis capabilities. The company aims to enter new markets in Asia and Europe by the end of 2025. The recent Series A funding, raised in April 2007, will support these initiatives by enabling further product development and marketing efforts to reach broader client bases.

## Funding rounds

- Series A, Apr 24, 2007, $0.1M — BPEA Private Equity, Village Ventures

## Investors

- BPEA Private Equity (https://capitalatlas.ai/funds/bpea-private-equity) — Series A
- Village Ventures (https://capitalatlas.ai/funds/village-ventures) — Series A